The technology, developed by Optimata Ltd., creates an in silico 'clone' for each patient, which can predict how the patient will respond to leading cancer drugs such as Adriamycin, Docetaxel, Paclitaxel, Vinorelbine and Tamoxifen. The goal is to improve the effectiveness of current breast cancer treatments, and to avoid the harsh and toxic treatments that patients must undergo. At present, a patient's schedule of chemotherapy treatment is based on trial-and-error.
"Breast cancer patients currently are all treated according to the same chemotherapy protocols," said Prof. Samuel Ariad, Head of Soroka's Institute of Oncology, "yet only between 15 to 65% of the patients respond to the chemotherapy. There is a need to find an empirical way of individualizing the therapy for each patient." Ariad, who heads the study, spoke with Israel21c.
Upon completion of the research, Optimata plans to use the Virtual Cancer Patient technology to provide clinical trials in order to recommend optimal dosing and scheduling regimens for actual breast cancer patients on an individual basis.
"Breast cancer patients currently are all treated according to the same chemotherapy protocols," said Prof. Samuel Ariad, Head of Soroka's Institute of Oncology, "yet only between 15 to 65% of the patients respond to the chemotherapy. There is a need to find an empirical way of individualizing the therapy for each patient." Ariad, who heads the study, spoke with Israel21c.
Upon completion of the research, Optimata plans to use the Virtual Cancer Patient technology to provide clinical trials in order to recommend optimal dosing and scheduling regimens for actual breast cancer patients on an individual basis.